An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CheckMate870
- Sponsors Bristol-Myers Squibb
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Jul 2018 Planned primary completion date changed from 29 Jul 2020 to 15 Jan 2019.
- 26 Mar 2018 Planned End Date changed from 30 Jul 2020 to 29 Jul 2022.